

Restoring Hearing. Advancing Healthy Aging.

Cilcare is a pioneering French-US biopharmaceutical company specializing in **auditory science**, developing cutting-edge solutions for the characterization, diagnosis, and treatment of hearing impairments and related disorders. Founded in 2014, Cilcare integrates therapeutics development, translational research, and AI-driven auditory analytics to address one of the world's largest unmet medical needs : hearing loss, a major risk factor for dementia and age-related diseases. The company has a proven track-record of **300+ deals** with **100+** life-sciences companies across North America, Europe, & Asia. Cilcare is committed to making hearing a priority for global health through disease-modifying therapies, advanced diagnostics, and precision-medicine solutions.

Cilcare addresses the global crisis of hearing disorders, a step closer to a cure

KEY FACTS ON HEARING LOSS

- 1 / 4 people by 2050
- 3rd cause of disability worldwide
- 1 bn young people at risk due to unsafe listening
- 1st risk factor for dementia

GLOBAL HEARING LOSS DISEASE TREATMENT MARKET

- \$12.5 Bn in 2025, expected to reach \$24 Bn by 2034
- CAGR: 5.23%
- No approved drug. Limited solutions from hearing aids

Cilcare: most advanced biotech in auditory sciences

THERAPEUTICS

Proprietary & Co-developed drug pipeline

A robust platform featuring multiple drug candidates, including a clinical-stage asset advancing directly into Phase 2a with a groundbreaking approach targeting cochlear synaptopathy

AUDITORY ANALYTICS

Digital auditory signatures

An AI-driven platform designed to visualize and analyze non-invasive digital hearing recordings, correlate them with non-auditory data, and deliver actionable biomarkers and early diagnostics—positioning hearing as a key pillar of a global preventive medicine strategy



CIL001, lead compound targeting first sign of hearing loss

CIL001 is an innovative drug candidate targeting **cochlear synaptopathy**, an early mechanism of hearing loss often associated with difficulty understanding speech in noisy environments, concerning **~15% of the population**. It is formulated as a long-acting gel for local inner-ear delivery through the tympanic membrane. By inducing neurotrophin production, CIL001 promotes synaptic repair between inner hair cells and auditory nerve fibers, restoring auditory signal transmission. CIL001 is ready to enter a Phase 2a clinical trial in Europe as a potential **disease-modifying therapy** for early-stage hearing loss.

What we are looking for

Financing our portfolio expansion, acquiring new assets, establishing new collaborations and strengthening our value chain through the integration of new businesses.

Investment • Assets in-licensing • R&D / KOL collaboration • M&A

CONTACT OUR TEAM !



Celia BELLINE
CEO & Co-founder
+33 6 37 88 20 95



Jérôme GEOFFROY
CFO
+33 6 48 81 71 92



Patricia MACHADO
Pipeline Director
+33 7 66 96 20 84



Gaëlle NAERT
COO & CSO
+33 6 74 00 69 41